

Food and Drug Administration Rockville MD 20857

JAN 22 1993

Re: SUPRANE™ Docket No. 92E-0471

#22

The Honorable Douglas B. Comer Acting Commissioner of Patents and Trademarks Washington, D.C. 20231

Dear Commissioner Comer:

This is in regard to the application for patent term extension for U.S. Patent No. 4,762,856, filed by Anaquest, Inc., under 35 U.S.C. § 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for SUPRANE™, the human drug product claimed by the patent.

The total length of the review period for SUPRANE™ is 1369 days. Of this time, 771 days occurred during the testing phase and 598 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: December 21, 1988.

FDA has verified the applicant's claim that the investigational new drug application (IND) became effective on December 21, 1988.

2. The date the application was initially submitted with respect to the human drug product under subsection 505(b)of the Federal Food, Drug, and Cosmetic Act: January 30, 1991.

FDA has verified the applicant's claim that NDA 20-118 was submitted on January 30, 1991.

3. The date the application was approved: September 18, 1992.

FDA has verified the applicant's claim that NDA 20-118 was approved on September 18, 1992.

Suprane™ - Page 2

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

Stuart L. Nightingale, M.D. Associate Commissioner for Health Affairs

cc: Hollis G. Schoepke, Ph.D.
Senior Vice President
Research and Development
Anaquest, Inc.
110 Allen Road
P.O. Box 804
Liberty Corner, N.J. 07938